DE­VEL­OP­ING News: Ac­celeron ne­go­ti­at­ing $11B buy­out; 11 promis­ing biotech star­tups; Changes ga­lore at No­var­tis; #ES­MO21 high­lights; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

This week I’ve been de­tached from dai­ly news writ­ing to fo­cus on an up­com­ing spe­cial re­port on Chi­na (and tak­ing some time to cel­e­brate the Mid-Au­tumn Fes­ti­val here in Hong Kong), but as you can see be­low, the rest of the team had lots of news and spe­cials for you. If you haven’t, be sure to watch our on­line events for #ES­MO21 and End­points 11, both avail­able on de­mand. You can find the ES­MO pan­el mod­er­at­ed by man­ag­ing ed­i­tor Kyle Blanken­ship here and the fire­side chat host­ed by founder John Car­roll here, fea­tur­ing a slate of guests with plen­ty of wis­dom to im­part.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.